Vertex Pharmaceuticals (VRTX) Technical analysis
Healthcare
Market data as of 2026-09-04 · Autonium metric computed 2026-09-04 · model v1VRTX technical analysis — the short answer
VRTX is classified Uptrend with a 14-day RSI of 59.4, three-month return of +22.2% and 20-day realised volatility of 32.8%. Autonium's composite Algo Score currently reads unavailable/100.
Price versus moving averages
Last close546.12
20-day538.78+1.4%
50-day508.76+7.3%
100-day474.65+15.1%
200-day466.15+17.2%
Trend classificationUptrend
Returns
1 week+0.8%
1 month+12.8%
3 months+22.2%
6 months+19.6%
12 months+37.6%
Volatility and drawdown
Realised volatility (20d, annualised)+32.8%
Realised volatility (60d, annualised)+29.7%
1-year volatility percentile75
Current drawdown from peak-2.1%
Deepest 1-year drawdown-15.2%
SPY volatility (20d)+8.1%
Autonium Algo Score
Current score—
7-day change—
30-day change—
90-day change—
1-year range—
Readings above 700
Readings below 300
Signal drivers
MomentumNeutral
Technical trendNeutral
VolatilityNeutral
SentimentNeutral
Sector peers — 3-month return
LLY — Eli Lilly and Co.1.6
UNH — UnitedHealth Group-0.6
JNJ — Johnson & Johnson18.2
ABBV — AbbVie Inc.12.9
MRK — Merck & Co.24.5
Bullish signals
- Price above the 50-day average
- Price above the 200-day average
- +17.8% three-month excess return vs SPY
Neutral signals
- RSI mid-range at 59.4
- Normal volume regime
Bearish signals
- Volatility in the 75th percentile of its own year
Track VRTX inside Autonium
Full factor detail, alerts when the score changes, and Toni to ask why.
Continue analysing VRTX
Autonium publishes research, not recommendations. Scores, factors and written reads describe historical and current data and are not buy or sell advice. Not financial advice. Market data is refreshed on a schedule and may lag. See our methodology and disclosures.